Panelists discuss how integrating both tissue and liquid genomic testing at diagnosis and progression improves detection of tumor heterogeneity and informs personalized treatment decisions in metastatic breast cancer.
Treatment Updates for Advanced or Metastatic Breast Cancer - SABCS
Panelists discuss how sequencing targeted therapies after CDK4/6 inhibitors differs for patients with actionable mutations versus those without, incorporating evidence for rechallenge and combination strategies.
Advertisement
Advertisement
Trending on CancerNetwork
1
Daratumumab Combo Yields Significantly Higher MRD Negativity in Multiple Myeloma
2
FDA Grants BTD to T-DXd in HER2+ BC With Residual Invasive Disease Post NAT
3
FDA Approves Subcutaneous Mosunetuzumab in R/R Follicular Lymphoma
4
JSKN003 Earns FDA Breakthrough Therapy Designation for HER2-Expressing PROC
5